Basic Platform Report: Leukemia Therapeutics

Published by: BioSeeker Group AB

Published: Oct. 26, 2004

Table of Contents

In each company profile the data is divided according to several different sections and subsections:

General information

Collaborations and alliances

Drug development pipeline (drug name, indications, developmental stages, effects of drugs, mechanism of actions, targets, combinatory treatments, general comments)

Abstract

Executive Summary

This "Basic Platform Report: Leukemia Therapeutics" report provides a complete and systematic description of the current R&D activities of already established as well as new innovative therapies for the treatment of leukemia (ALL CLL, AML and CML). This informative report includes extensive presentations of more than 60 of the most important companies active in this field. The focus has been to review the R&D activities and partnerships in different therapeutic strategies. Hundreds of pipeline drugs and a majority of B2B collaboration and industry-academic alliances are included.

Each company profile contains contact data, a short description of the company, partnership activities, pipeline activities, patents and description of products already at market.

With the help of the company index of more than 60 firms collaborations can easily be track down any player in the field identified. The "Basic Platform Report: Leukemia Therapeutics" is an excellent source of information that provides you with a solid presentation of this exciting and rapidly evolving field.

Related patents Some of the drugs included in the report:

AG-858, AP23573, Avastin, Atragen, BAY 43-9006, Bryostatin-1, Campath, Ceplene, CEP-701, Clofarabine, Cloretazine, Decitabine, FK228, Flavopiridol, Genasense, Gleevec, GVAX, Mylotarg, Multiferon, OSI-461, Phenoxodiol, pentostatin, PEG-Interferon, PKC412, PTK787, Revlimid, Rituxan, SU5416, SCH 54031, Sarasar, Triapine, Tezacitabine, Troxacitabine, Trisenox, valspodar, Velcade, Zamyl, Zarnestra, Xcytrin, XL999

Some of the companies included in the report: Aventis, Antigenics, Biogen/ IDEC, Berlex Laboratories, Inc., Corixa Corporation, Celgene Corporation, Chiron, Cephalon Inc, Genentech, Exelixis Inc, Genta Incorporated, GlaxoSmithKline, ILEX Oncology Inc., Immuno-Designed Molecules, IDM, Immunex Corp, J&J PRD, Ligand Pharmaceuticals, Maxim Pharmaceuticals, Medarex, Merck, Millennium Pharma., Novartis, OSI Pharmaceuticals, Point Therapeutics, Protein Design Labs, Pfizer (Pharmacia), Pharmatech Oncology, Pharmasset, Inc., Pharmacyclics, Schering-Plough, Supergen, Roche, Schering AG, Schering Corporation, Shire Pharmaceuticals, Seragen, Vion Pharmaceuticals, Inc.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.